IL17A and breast carcinoma: As a future development, it will be interesting to understand whether IL17 inhibitors (no less than 3 of which are currently approved for use in patients with psoriasis and other inflammatory conditions)14 or CSF1R inhibitors such as pexidartinib and vimseltinib (which are currently approved for use in patients with tenosynovial giant cell tumors)15,16 can be safely and effectively combined with CDK4/6 inhibitors in patients with HR+HER2− breast cancer that are not eligible to SBRT.